Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.

Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB 3rd, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA; National Comprehensive Cancer Networks.

J Natl Compr Canc Netw. 2012 Jun 1;10(6):703-13.

2.

Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines.

Tempero MA, Malafa MP, Behrman SW, Benson AB 3rd, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA.

J Natl Compr Canc Netw. 2014 Aug;12(8):1083-93.

PMID:
25099441
3.

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB 3rd, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S.

J Natl Compr Canc Netw. 2017 Aug;15(8):1028-1061. doi: 10.6004/jnccn.2017.0131.

PMID:
28784865
4.

CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.

Wagner M, Antunes C, Pietrasz D, Cassinotto C, Zappa M, Sa Cunha A, Lucidarme O, Bachet JB.

Eur Radiol. 2017 Jul;27(7):3104-3116. doi: 10.1007/s00330-016-4632-8. Epub 2016 Nov 28.

PMID:
27896469
5.

Pancreatic cancer: FDG-PET is not useful in early pancreatic cancer diagnosis.

Strobel O, Büchler MW.

Nat Rev Gastroenterol Hepatol. 2013 Apr;10(4):203-5. doi: 10.1038/nrgastro.2013.42. Epub 2013 Mar 12. No abstract available.

PMID:
23478386
6.

How to treat pancreatic adenocarcinoma in elderly: How far can we go in 2017?

Gilabert M, Raoul JL, Rousseau F.

J Geriatr Oncol. 2017 Nov;8(6):407-412. doi: 10.1016/j.jgo.2017.08.007. Epub 2017 Sep 6. Review.

PMID:
28888554
7.

Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology.

Tempero MA, Behrman S, Ben-Josef E, Benson AB 3rd, Cameron JL, Casper ES, Hoffman JP, Karl RC, Kim P, Koh WJ, Kuvshinoff BW 2nd, Melvin WS, Muscarella P 2nd, Sasson AR, Shibata S, Shrieve DC, Talamonti MS, Tyler DS, Vickers SM, Warren RS, Willett C, Wolff RA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2005 Sep;3(5):598-626. No abstract available.

PMID:
16194453
9.

Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines.

Benson AB 3rd, Arnoletti JP, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF, Enzinger PC, Fakih MG, Fleshman JW Jr, Fuchs CS, Grem JL, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett C, Freedman-Cass DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Apr;10(4):449-54.

PMID:
22491045
10.

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.

Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopterides P, Loukeris D, Sigala F, Zorbala-Sypsa A, Felekouras E, Papalambros E.

Invest New Drugs. 2005 Aug;23(4):369-75. Erratum in: Invest New Drugs. 2005 Dec;23(6):603. Kopteridis, Petros [corrected to Kopterides, Petros].

PMID:
16012797
11.

Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines.

Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA.

J Natl Compr Canc Netw. 2013 Feb 1;11(2):141-52; quiz 152.

PMID:
23411381
12.

Diagnosis and management of pancreatic cancer.

Kanji ZS, Gallinger S.

CMAJ. 2013 Oct 1;185(14):1219-26. doi: 10.1503/cmaj.121368. Epub 2013 Apr 22. Review. No abstract available.

13.

Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.

Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA.

J Natl Compr Canc Netw. 2012 Sep;10(9):1081-7.

PMID:
22956807
14.

Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma.

Singapore Cancer Network (SCAN) Pancreatic Cancer Workgroup.

Ann Acad Med Singapore. 2015 Oct;44(10):388-96.

15.

[Pancreatic adenocarcinoma: therapeutical update].

Khosravi Shahi P, Díaz Muñoz de la Espada VM.

An Med Interna. 2005 Aug;22(8):390-4. Review. Spanish.

PMID:
16351494
16.

Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.

Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, Clark JW, Faris JE, Goyal L, Kwak EL, Murphy JE, Ting DT, Wo JY, Zhu AX, Warshaw AL, Lillemoe KD, Fernández-del Castillo C.

Ann Surg. 2015 Jan;261(1):12-7. doi: 10.1097/SLA.0000000000000867.

17.

Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer.

Rashid OM, Pimiento JM, Gamenthaler AW, Nguyen P, Ha TT, Hutchinson T, Springett G, Hoffe S, Shridhar R, Hodul PJ, Johnson BL, Illig K, Armstrong PA, Centeno BA, Fulp WJ, Chen DT, Malafa MP.

Ann Surg Oncol. 2016 Apr;23(4):1371-9. doi: 10.1245/s10434-015-5006-1. Epub 2015 Dec 10.

PMID:
26661409
18.

Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes.

Visser BC, Ma Y, Zak Y, Poultsides GA, Norton JA, Rhoads KF.

HPB (Oxford). 2012 Aug;14(8):539-47. doi: 10.1111/j.1477-2574.2012.00496.x. Epub 2012 Jun 12.

19.

Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines.

Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 May 1;11(5):519-28.

PMID:
23667203
20.

Interventional endoscopy, neoadjuvant therapy and the gastroenterologist.

Snady H.

Hematol Oncol Clin North Am. 2002 Feb;16(1):53-79. Review.

PMID:
12063829

Supplemental Content

Support Center